United Kingdom
Ireland United KingdomFranceDeutschlandItalianSpanishChina

Breathing life into medicines

Business Development

We have strong track record of successful acquisitions, having completed 28 acquisitions and a number of in-licensing deals over the past 16 years, with a combined deal value in excess of £225 million.

Alliance’s growth strategy is underpinned by a continuing focus on acquisitions and in-licensing opportunities, in order to bring new products into the business. 

To enable us to deliver on our strategy, the group has a dedicated Business Development team who actively seek out acquisition and licensing opportunities.  We have considerable expertise in target selection, contract negotiation and integration of acquired products into our business operations.

A history of sales stability or the potential for growth is our primary interest when assessing acquisition opportunities.

We also have considerable financial resources available to enable us to fund future deals. 

If you have a business development opportunity you’d like to discuss, please email us at bd@alliancepharmaceuticals.com or call our switchboard on +44 (0) 1249 466966.
 

Deal History

December 2015

Sinclair Healthcare Products

February 2015

MacuVision

January 2014

Irenat

December 2013

Lypsyl

June 2013

Syntometrine

Read more